BIOMAT Database Logo BIOMAT Database Logo

Effects of risedronate on bone turnover markers in osteoporotic postmenopausal women: comparison of two protocols of treatment. 2009

Afef Bahlous, and Kahena Bouzid, and Héla Sahli, and Slaheddine Sallami, and Jaouidia Abdelmoula
Department of Clinical Biochemistry, Charles Nicolle Hospital, Tunis.

BACKGROUND Bisphosphonates are powerful agents able to prevent bone loss. OBJECTIVE The objective of the study was to evaluate the efficacy and tolerability of risedronate once a week (35 mg) compared with risedronate 5 mg once daily in women with osteoporosis. METHODS A randomized, double-blind, active-controlled study enrolled 102 postmenopausal women aged 66.5+/-7.5 years with osteoporotic fractures. All women received risedronate during 6 months. Group 1 (G1, n=51) received risedronate 5 mg once daily and group 2 (G2, n=51) received 35 mg once a week. Serum alkaline phosphatase (ALP), bone alkaline phosphatase (bone ALP), serum C-terminal telopeptide of type I collagen (CTX) were measured at baseline, 3 months and 6 months after treatment in the two groups. RESULTS We noted no significant difference in markers between women of the 2 groups. After 3 months, bone ALP and CTX decreased (respectively -22.1% and -47.6%) in the 2 groups with no significant difference between them. After 6 months study, bone ALP and CTX decreased respectively by -46.5% and -62.9% with no statistically significant difference between study groups for bone markers. CONCLUSIONS Our study found that treatment with once weekly risedronate 35 mg is able to decrease CTX and bone ALP compared with risedronate 5 mg once daily, in postmenopausal women with osteoporotic fractures. We didn't find adverse events with the 35 mg once-a-week dose group compared to the once-daily dose group. Based on these results, the effects of risedronate 35 mg once a week are similar in efficacy to daily dosing and may lead less adverse events than once-a-month dose. This therapeutic protocol may provide an alternative for patients who prefer once-a-week oral dosing.

UI MeSH Term Description Entries
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D010455 Peptides Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are considered to be larger versions of peptides that can form into complex structures such as ENZYMES and RECEPTORS. Peptide,Polypeptide,Polypeptides
D011347 Procollagen A biosynthetic precursor of collagen containing additional amino acid sequences at the amino-terminal and carboxyl-terminal ends of the polypeptide chains. Protocollagen,Procollagen Type M
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000068296 Risedronic Acid A pyridine and diphosphonic acid derivative that acts as a CALCIUM CHANNEL BLOCKER and inhibits BONE RESORPTION. Bisphosphonate Risedronate Sodium,1-Hydroxy-2-(3-pyridyl)ethylidene diphosphonate,2-(3-pyridinyl)-1-hydroxyethylidene-bisphosphonate,2-(3-pyridinyl)-1-hydroxyethylidenebisphosphonate,Actonel,Atelvia,Risedronate,Risedronate Sodium,Risedronic Acid, Monosodium Salt,Risedronate Sodium, Bisphosphonate,Sodium, Bisphosphonate Risedronate
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

Afef Bahlous, and Kahena Bouzid, and Héla Sahli, and Slaheddine Sallami, and Jaouidia Abdelmoula
Short-term risedronate treatment in postmenopausal women: effects on biochemical markers of bone turnover.
January 2000, Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA,
Afef Bahlous, and Kahena Bouzid, and Héla Sahli, and Slaheddine Sallami, and Jaouidia Abdelmoula
Comparison of monthly ibandronate versus weekly risedronate in preference, convenience, and bone turnover markers in Korean postmenopausal osteoporotic women.
November 2009, Calcified tissue international,
Afef Bahlous, and Kahena Bouzid, and Héla Sahli, and Slaheddine Sallami, and Jaouidia Abdelmoula
Effects of alendronate and risedronate on bone mineral density and bone turnover markers in late postmenopausal women with osteoporosis.
January 2006, Advances in therapy,
Afef Bahlous, and Kahena Bouzid, and Héla Sahli, and Slaheddine Sallami, and Jaouidia Abdelmoula
Comparison of the effects of alendronate and risedronate on bone mineral density and bone turnover markers in postmenopausal osteoporosis.
January 2006, Rheumatology international,
Afef Bahlous, and Kahena Bouzid, and Héla Sahli, and Slaheddine Sallami, and Jaouidia Abdelmoula
Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment.
December 1994, The Journal of clinical endocrinology and metabolism,
Afef Bahlous, and Kahena Bouzid, and Héla Sahli, and Slaheddine Sallami, and Jaouidia Abdelmoula
Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis.
April 2007, The Journal of clinical endocrinology and metabolism,
Afef Bahlous, and Kahena Bouzid, and Héla Sahli, and Slaheddine Sallami, and Jaouidia Abdelmoula
Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis.
November 2002, Bone,
Afef Bahlous, and Kahena Bouzid, and Héla Sahli, and Slaheddine Sallami, and Jaouidia Abdelmoula
Head-to-head comparison of risedronate vs. teriparatide on bone turnover markers in women with postmenopausal osteoporosis: a randomised trial.
June 2008, International journal of clinical practice,
Afef Bahlous, and Kahena Bouzid, and Héla Sahli, and Slaheddine Sallami, and Jaouidia Abdelmoula
Effects of alendronate on bone turnover markers in early postmenopausal women.
October 1998, Zhonghua yi xue za zhi = Chinese medical journal; Free China ed,
Afef Bahlous, and Kahena Bouzid, and Héla Sahli, and Slaheddine Sallami, and Jaouidia Abdelmoula
Effects of odanacatib on bone-turnover markers in osteoporotic postmenopausal women: a post hoc analysis of the LOFT study.
October 2022, Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA,
Copied contents to your clipboard!